VERDI Solutions, GmbH

Founded

2022

Staff

4

Organization type

RDM biotech/pharma

Cluster

LISAvienna

VERDI Solutions GmbH, a Vienna-based startup, develops cutting-edge technology for personalized cancer vaccines. Our innovations include diagnostic tests for HLA-based T-cell responses, HLA expression analysis, and personalized vaccine target identification. Our proprietary software predicts the immunogenicity, safety, and quality of vaccines at the individual level. Our mission is to provide safe, effective personalized vaccines to improve the health of cancer patients.

R&D:VERDI Solutions GmbH focuses on developing personalized cancer vaccines through advanced diagnostic tests and proprietary software. Our research includes HLA-based T-cell response diagnostics, HLA expression analysis, and personalized target identification. We aim to predict immunogenicity, safety, and vaccine quality at the individual level, striving to create effective, tailored immunotherapies that enhance patient health and treatment outcomes.

Production:VERDI Solutions GmbH is preparing to start clinical trials with double-personalized peptide vaccines. Each vaccine is uniquely tailored to the specific patient and the cancer, ensuring a highly individualized treatment approach. Unlike mass-produced vaccines, our vaccines are produced individually, not industrially, to meet the unique needs of each patient. This personalized production process aims to maximize the effectiveness and safety of cancer immunotherapy.

Services:VERDI Solutions GmbH offers a range of services focused on personalized cancer treatment. We provide advanced diagnostic tests for HLA-based T-cell responses and HLA expression analysis. Our proprietary software identifies personalized targets and predicts the immunogenicity, safety, and quality of vaccines at the individual level. We develop and produce unique peptide vaccines tailored to each patient's specific cancer, aiming to enhance treatment effectiveness and patient health outcomes.